Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-01-31
DOI
10.3389/fonc.2020.00001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
- (2019) Shaji K. Kumar et al. LEUKEMIA
- Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study
- (2019) Theresa E. Hahn et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Surrogate endpoints in randomised controlled trials: a reality check
- (2019) Shaji Kumar et al. LANCET
- Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA
- (2019) Herve Avet-Loiseau et al. Clinical Lymphoma Myeloma & Leukemia
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal residual disease in multiple myeloma: use of magnetic resonance imaging
- (2018) Jens Hillengass et al. SEMINARS IN HEMATOLOGY
- MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment
- (2018) Ola Landgren et al. SEMINARS IN HEMATOLOGY
- Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease
- (2018) Katie L. Thoren SEMINARS IN HEMATOLOGY
- Longitudinal Flow Cytometry Identified “Minimal Residual Disease” (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma
- (2018) Jingli Gu et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
- (2018) Aurore Perrot et al. BLOOD
- Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials
- (2018) Mattia D’Agostino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
- (2018) Meletios A. Dimopoulos et al. HAEMATOLOGICA
- Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
- (2018) Manuela Gambella et al. CANCER
- Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma
- (2018) L. Rasche et al. LEUKEMIA
- Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
- (2017) Juan-Jose Lahuerta et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
- (2017) Philippe Moreau et al. JOURNAL OF CLINICAL ONCOLOGY
- Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
- (2017) J Flores-Montero et al. LEUKEMIA
- Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
- (2017) J Martinez-Lopez et al. LEUKEMIA
- Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma
- (2017) N Lee et al. Blood Cancer Journal
- High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma
- (2017) J R Mills et al. Blood Cancer Journal
- 11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions
- (2017) Constantin Lapa et al. Theranostics
- Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma
- (2017) Nikhil C. Munshi et al. JAMA Oncology
- Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
- (2016) B. Paiva et al. BLOOD
- Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
- (2016) O Landgren et al. BONE MARROW TRANSPLANTATION
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
- (2015) A. C. Rawstron et al. BLOOD
- Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up
- (2015) Heinz Ludwig et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration
- (2015) H. R. Bergen et al. CLINICAL CHEMISTRY
- Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition
- (2015) Maryalice Stetler-Stevenson et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma
- (2015) Juan Flores-Montero et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?
- (2015) C Pawlyn et al. LEUKEMIA
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
- (2015) Neha Korde et al. JAMA Oncology
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
- (2014) J. Martinez-Lopez et al. BLOOD
- Quality assessment program for EuroFlow protocols: Summary results of four-year (2010-2013) quality assurance rounds
- (2014) Tomas Kalina et al. CYTOMETRY PART A
- Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome
- (2014) Murielle Roussel et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
- (2014) S Ferrero et al. LEUKEMIA
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
- (2013) Andy C. Rawstron et al. JOURNAL OF CLINICAL ONCOLOGY
- Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
- (2013) N Puig et al. LEUKEMIA
- Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
- (2013) M Ladetto et al. LEUKEMIA
- Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma”
- (2013) Jens Hillengass et al. LEUKEMIA & LYMPHOMA
- Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
- (2012) M. Faham et al. BLOOD
- The role of imaging techniques in the management of multiple myeloma
- (2012) Elena Zamagni et al. BRITISH JOURNAL OF HAEMATOLOGY
- Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma
- (2012) J. Hillengass et al. HAEMATOLOGICA
- The Level of Minimal Residual Disease in the Bone Marrow of Patients with Multiple Myeloma before High-Dose Therapy and Autologous Blood Stem Cell Transplantation Is an Independent Predictive Parameter
- (2011) Mark Korthals et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- PET-CT in MM: a new definition of CR
- (2011) P. Moreau BLOOD
- High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
- (2011) B. Paiva et al. BLOOD
- Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
- (2011) E. Zamagni et al. BLOOD
- Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology
- (2011) Jens Hillengass et al. BRITISH JOURNAL OF HAEMATOLOGY
- Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach
- (2011) Joan Bladé et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
- (2011) Bruno Paiva et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
- (2010) Marco Ladetto et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started